Summary
Low molecular weight (LMW) heparin Kabi 2165 possesses improved pharmacodynamic properties compared with conventional heparin. It is currently investigated in the prophylaxis of thromboembolism. The neutralization of Kabi 2165 by protamine chloride was analysed after i.v. injection of both the agent and the antidot in healthy persons. The anticoagulant effects of the LMW heparin on the activated partial thromboplastin time, thrombin, and thromboelastography are completely and immediately suppressed by protamine chloride. The inhibition of factor X a is antagonized up to 50%–60%. The bleeding time remained unaffected. The data indicate that protamine chloride may be used in clinical situations as an antidot to the LMW heparin Kabi 2165. A rebound phenomenon of the anticoagulant effect does not occur.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- aPTT:
-
aktivierte partielle Thromboplastinzeit
- MW:
-
Molecular weight
- R-Zeit:
-
Reaktionszeit
- TEG:
-
Thrombelastogramm
Literatur
Barrowcliffe TW, Johnson EA, Eggleton CA, Thomas DP (1977) Anticoagulant activities of lung and mucous heparins. Thromb Res 12:27–36
Benayahu D, Aronson M (1983) Comparative study of protamine chloride and sulphate in relation to the heparin rebound phenomenon. Thromb Res 32:109–114
Bergquist D, Hedner U, Sjörin E, Holmer E (1983) Anticoagulant effect of two types of low molecular weight heparin administered subcutaneously. Thromb Res 32:381–391
Chargraff E, Olson KB (1937) Studies on the chemistry of blood coagulation. IV. Studies on the action of the heparin and other coagulants. The influence of protamine on the anticoagulant effect in vivo. J Biol Chem 122:153–167
Denton I, Lane DA, Thunberg L, Slater AM, Lindahl U (1983) Binding of platelet factor 4 to heparin oligosaccharides. Biochem J 209:455–462
Fabian J, Aronson M (1980) Mechanism of heparin rebound. Thromb Res 18:535–542
Frick PG, Brögli H (1966) The mechanism of heparin rebound after extracorporal circulation of open cardiac surgery. Surgery 59:721–726
Harenberg J, de Vries JX (1983) Characterization of heparins by high performance size exclusion liquid chromatography. J Chromatogr 261:287–292
Harenberg J, de Vries JX, Weber E, Zimmermann R (1984) Beeinflussung der Blutgerinnung durch ein niedermolekulares Heparin. Dtsch Med Wschr 109:951–954
Harenberg J, Gnasso A, de Vries JX, Zimmermann R, Augustin J (1985) Anticoagulant and lipolytic effects of a low molecular weight heparin fraction. Thromb Res 39:683–692
Harenberg J, Gnasso A, de Vries JX, Zimmermann R, Augustin J (1985) Inhibition of low molecular weight heparin by protamine chloride in vivo. Thromb Res 38:11–20
Hartert H (1951) Die Thrombelastographie. Eine Methode zur physikalischen Analyse des Blutgerinnungsvorganges. Zeitschr Ges Exp Med 117:189–203
Holmer E, Kurachi K, Söderström G (1981) The molecularweight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIIa and kallikrein by antithrombin. Biochem J 193:395–400
Holmer E, Mattsson C, Nilsson S (1982) Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. Thromb Res 25:475–485
Holmer E, Söderström G (1983) Neutralization of unfractionated heparin and a low molecular weight (LMW) heparin fragment by protamine. Thrombos Haemostas 50:103
Jorpes E, Edmann P, Thaning T (1939) Neutralization-of action of heparin by protamine. Lancet 2:975–976
Kakkar VV, Corrigan TP, Fossard DP (1975) Prevention of fatal postoperative pulmonary embolism by low-doses of heparin. Lancet II:45
Kakkar VV, Djazaeri B, Fok J, Fletcher M, Scully MF, Westwick J (1982) Low-molecular weight heparin and prevention of postoperative deep-vein thrombosis. Br Med J 284:375–379
Kakkar VV (1984) Prevention of post-operative venous thromboembolism by a new low molecular weight heparin fraction. Nouv Rev Fr Hematol 26:277–282
Mielke HC (1984) Measurement of the bleeding time. Thrombos Haemostas 52:210–211
Ockelford PA, Carter CJ, Mitchell L, Hirsh J (1982) Discordance between the anti-Xa activity and antithrombotic activity of an ultra-low molecular weight heparin fraction. Thromb Res 28:401–409
Oosta GM, Gardner WT, Beller DL, Rosenberg RD (1981) Multiple functional domains of the heparin molecule. Proc Natl Acat Sci 78:829–833
Schmitz-Huebner U, Bünte H, Freise G, Reers B, Rüschemeyer C, Scherer R, Schulte H, van de Loo J (1984) Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis. Klin Wschr 62:349–353
Schrader J, Rieger J, Müschen H, Stribbe W, Köstering H, Kramer P, Scheler F (1985) Anwendung von niedermolekularem Heparin bei Hämodialysepatienten. Klin Wschr 63:49–55
Teien AN, Lie M (1975) Heparin assay in plasma: A comparison of five clotting methods. Thromb Res 7:777–785
Warlow Ch, Beattie AG, Terry G, Ogston D, Kenmure CF, Douglas AS (1973) A douple-blind treal of low doses of subcutaneous heparin in the prevention of deep-vein thrombosis after myocardial infarction. Lancet II:934
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Harenberg, J., Giese, C., Knödler, A. et al. Neutralisierung von niedermolekularem Heparin Kabi 2165 mit Protaminchlorid. Klin Wochenschr 64, 1171–1175 (1986). https://doi.org/10.1007/BF01728455
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01728455